AUTEL-ENERGY-EUROPE
1.5.2024 10:52:35 CEST | Business Wire | Press release
Autel Energy Europe, a leading provider of EV charging products and services, has successfully concluded its Autel Partner Summit at the prestigious Muziekgebouw in Amsterdam. From April 24th to 25th, the summit not only showcased Autel’s visionary Europe strategy but also provided partners with unique insights into the company's vision and a comprehensive overview of Autel’s latest revolutionary product line.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501790167/en/
Autel Energy Europe Hosts 2024 Partner Summit in Amsterdam (Photo: Business Wire)
The summit brought together influential figures, key players from the EV industry, esteemed clients, and industry members for engaging discussions and presentations. Notable speakers from industry giants such as Hubject shared their expertise and insights into the future of electric mobility, enriching discussions and inspiring attendees to push the boundaries of innovation in EV charging infrastructure.
Autel unveiled its newest innovations at the summit, headlined by the MaxiCharger Megawatt Charging System, offering peak power of 1500A and 1.2 MW charging power. Tailored for heavy-duty electrical vehicles, it accommodates diverse user cases such as public overnight charging and depot charging. Additionally, Autel introduced the MaxiCharger DC Compact - Cable Management System Upgrade Version and the Autel Smart Box Kit, showcasing its commitment to advancing EV charging technology.
On the second day of the Partner Summit 2024, Autel organized a special visit for clients to their partner, Orange Charging, to experience the unveiling of Autel's MaxiCharger DC HiPower. This cutting-edge charging solution features state-of-the-art technology, including the Max. 640kw charging system, delivering up to 400km of range in just 10 minutes. Moreover, its intelligent Power Distribution capability enables simultaneous charging of up to 8 vehicles, enhancing efficiency and utilization of charging infrastructure.
Ting Cai, CEO of Autel Europe, stated, "With notable speakers from industry leaders like Hubject, the summit reflects our commitment to driving innovation in the EV industry. Our groundbreaking technologies, such as the MaxiCharger Megawatt Charging System and the MaxiCharger DC HiPower, demonstrate our dedication to revolutionizing EV charging infrastructure and shaping a cleaner, more efficient future for mobility."
Highlighting Autel Energy's remarkable financial growth, the company has experienced significant success in the European market over the past four years. This underscores Autel's position as a leading player in the EV charging sector and its commitment to driving progress in sustainable transportation.
Additionally, the Megawatt Charging System will be displayed at Power2Drive Europe C6-330 in Munich in June. We welcome all attendees to visit our booth and explore the cutting-edge features of the Megawatt Charging System firsthand.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501790167/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom